Seismic Therapeutic to Attend Multiple Scientific Conferences in June 2024

Seismic Therapeutic, Inc., a company specializing in machine learning and immunology, has announced its participation in three upcoming scientific conferences. The company will present data on its novel therapeutics for autoimmune diseases and its proprietary IMPACT platform, which utilizes machine learning for biologics drug discovery. Two main drug candidates will be highlighted: S-1117, a novel pan-immunoglobulin G protease, and S-4321, a dual-cell bidirectional antibody.

The first event is the Structure Based Drug Design Summit in Boston, MA, from June 11-13. Seismic Therapeutic's presentation, titled "Structure Empowered IMPACT Platform in the Discovery & Development of Immunoglobulin Sculpting Enzyme & Dual-Cell Bidirectional Antibody Drugs for Immunological Diseases," will occur on June 13. Yi Xing, PhD, Senior Director of Drug Creation, will lead the session. Additionally, a poster on "Structural Basis for Fc Domain Selectivity to FcgRIIB" will be presented by Colin Lipper, PhD, Senior Scientist, at the afternoon break and poster session on June 12.

The second conference is the Federation of Clinical Immunology Societies (FOCIS) 2024 Annual Meeting in San Francisco, CA, from June 18-21. Seismic Therapeutic will present two posters. The first, titled "Identification and Characterization of PD-1 Agonists for the Treatment of Autoimmune and Inflammatory Diseases," will be presented by Mike Cianci, M.S. on June 18. The second poster, "Preclinical Pharmacology of S-1117, a Novel Engineered Fc-fused IgG Cleaving Enzyme, for Chronic Treatment of Autoantibody-mediated Diseases," will be presented by Ivan Mascanfroni, PhD, on June 19.

The third event is the ESACT - European Society for Animal Cell Technology conference in Edinburgh, Scotland, from June 23-26. Seismic Therapeutic will present on "Mitigating Risk During Biologics Manufacturing Using Discovery Stage Developability Assays and State of the Art Machine Learning Based Optimization" on June 26. Jyothsna Visweswaraiah, PhD, Director of Drug Creation, will deliver the presentation.

Seismic Therapeutic is a biotechnology company that leverages machine learning to revolutionize the discovery and development of immunology therapies. The company's preclinical pipeline consists of best-in-class and first-in-class biologics aimed at controlling dysregulated adaptive immunity to treat various autoimmune diseases. Seismic Therapeutic is supported by a consortium of life sciences investors and operates out of Boston's biotechnology hub.